Literature DB >> 21750158

FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart.

Martin L Ford1, Edward R Smith, Laurie A Tomlinson, Prabal K Chatterjee, Chakravarthi Rajkumar, Stephen G Holt.   

Abstract

BACKGROUND: Extra-skeletal calcification and disordered phosphate metabolism are hallmarks of chronic kidney disease-mineral bone disorder (CKD-MBD). Osteoprotegerin (OPG) and fibroblast growth factor 23 (FGF-23) are increased in chronic kidney disease (CKD) and have been associated with arterial and cardiac dysfunction and reduced survival. Troponin T (cTnT) is released from cardiac myocytes under conditions of stress and is predictive of mortality across a range of renal functions. However, the utility of this biomarker was formerly limited by the lower limit of assay detection. The introduction of a high-sensitivity assay has enabled more detailed study of myocyte stress below the previous limit of detection. We studied the association of mediators of CKD-MBD with arterial stiffness and also of these mediators and arterial stiffness with myocardial damage in patients with CKD stages 3-4.
METHODS: OPG and FGF-23 were measured in 200 CKD stages 3-4 patients. cTnT was measured using a high-sensitivity assay. Aortic stiffness was assessed using aortic pulse wave velocity (APWV).
RESULTS: Mean age was 69 ± 11 years, mean systolic and diastolic blood pressure was 151 ± 22/81 ± 11 mmHg and renal function was 33 ± 11 mL/min/1.73 m(2). OPG, FGF-23, high-sensitivity troponin T (hs-cTnT) and APWV all correlated with renal function. After multivariate analysis, OPG and age remained independently associated with aortic stiffness. OPG and FGF-23 were independently associated with hs-cTnT in addition to other non-traditional risk factors (Model R(2) = 0.596).
CONCLUSION: We have shown that changes in bone mediators and phosphate metabolism induced by CKD are independently associated with vascular and cardiomyocyte dysfunction. Our findings suggest that cardiac dysfunction may be specifically associated with such abnormalities in addition to recognized increases in vascular stiffness.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21750158     DOI: 10.1093/ndt/gfr316

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  17 in total

1.  What's new in FGF23 research?

Authors:  Seiji Fukumoto
Journal:  Bonekey Rep       Date:  2012-07-04

Review 2.  Osteoprotegerin and kidney disease.

Authors:  Alejandra Montañez-Barragán; Isaias Gómez-Barrera; Maria D Sanchez-Niño; Alvaro C Ucero; Liliana González-Espinoza; Alberto Ortiz
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

3.  Lack of predictive value of FGF23 levels on pulse wave velocity.

Authors:  L Desjardins; S Liabeuf; Z A Massy
Journal:  Osteoporos Int       Date:  2012-08-09       Impact factor: 4.507

4.  FGF23: instability may affect accuracy and interpretation.

Authors:  E R Smith; L P McMahon; S G Holt
Journal:  Osteoporos Int       Date:  2012-08-09       Impact factor: 4.507

Review 5.  Genetic variants of mineral metabolism in health and disease.

Authors:  Cassianne Robinson-Cohen
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 2.894

6.  FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients.

Authors:  Diana Moldovan; Ioan Moldovan; Crina Rusu; Ina Kacso; Ioan Mihai Patiu; Mirela Gherman-Caprioara
Journal:  Int Urol Nephrol       Date:  2013-04-03       Impact factor: 2.370

7.  Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Jeffrey J Hsu; Ronit Katz; Joachim H Ix; Ian H de Boer; Bryan Kestenbaum; Michael G Shlipak
Journal:  Nephrol Dial Transplant       Date:  2014-04-29       Impact factor: 5.992

Review 8.  Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease.

Authors:  Tamara Isakova
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

9.  FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.

Authors:  Chad D Touchberry; Troy M Green; Vladimir Tchikrizov; Jaimee E Mannix; Tiffany F Mao; Brandon W Carney; Magdy Girgis; Robert J Vincent; Lori A Wetmore; Buddhadeb Dawn; Lynda F Bonewald; Jason R Stubbs; Michael J Wacker
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-02-26       Impact factor: 4.310

10.  Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD.

Authors:  Kelsey Smith; Christopher deFilippi; Tamara Isakova; Orlando M Gutiérrez; Karen Laliberte; Stephen Seliger; Walter Kelley; Show-Hong Duh; Michael Hise; Robert Christenson; Myles Wolf; James Januzzi
Journal:  Am J Kidney Dis       Date:  2012-08-09       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.